Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitor therapy: a case report

G Klinkner, M Steingraber-Pharr - AACN Advanced Critical Care, 2023 - AACN
Sodium-glucose cotransporter-2 inhibitors are now considered second-line treatment agents
for type 2 diabetes and offer a unique treatment approach with added cardiorenal benefits …

Antidiabetic Advancements In Silico: Pioneering Novel Heterocyclic Derivatives through Computational Design

A Mehra, A Mehra - Current Signal Transduction Therapy, 2024 - ingentaconnect.com
Background: Deficiency of insulin signaling in type 2 diabetes results from insulin resistance
or defective insulin secretion and induced hyperglycemia. By reducing glycated hemoglobin …

[HTML][HTML] Detection of Euglycemic Diabetic Ketoacidosis During Thoracic Surgery 75 Hours After Empagliflozin Discontinuation

A Nishida, O Ogawa, H Takizawa - Cureus, 2022 - ncbi.nlm.nih.gov
Euglycemic diabetic ketoacidosis (eDKA) has been increasingly reported as an adverse
event of sodium-glucose cotransporter 2 inhibitors (SGLT2i), and the accompanying …

Insilico designing of novel imidazothiadiazole derivatives as SGLT2 inhibitors in emerging potential for Antidiabetic Therapeutics

A Mehra - 2023 - researchsquare.com
Background. Deficiency of insulin signaling in type 2 diabetes results from insulin resistance
or defective insulin secretion and induce hyperglycemia. By reducing glycated hemoglobin …

[引用][C] Acidosis and aspiration: Popular diabetes medications and the risks they pose in the perioperative period.

MM Weber, RK Price, PF Mack - Journal of Clinical Anesthesia, 2024 - europepmc.org
Acidosis and aspiration: Popular diabetes medications and the risks they pose in the
perioperative period. - Abstract - Europe PMC Sign in | Create an account https://orcid.org …